Analysts expect Radiopharm Theranostics Ltd to report revenue of 1.81 M for 2027, against a range of 1.66 M to 1.95 M. The most recent reported year, 2026, came in at 1.99 M, a 29.1% beat against the 1.54 M consensus.
| Metric | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 189,350.00 | 203,030.00 | 2.38 M | 1.99 M | - | - | ||
| High Estimate | 223,625.56 | 0.00 | 795,635.25 | 1.69 M | 1.95 M | 2.93 M | ||
| Low Estimate | 188,880.58 | 0.00 | 740,621.89 | 1.39 M | 1.66 M | 2.47 M | ||
| Consensus Estimate | 206,253.07 | 0.00 | 768,128.57 | 1.54 M | 1.81 M | 2.70 M |
Analysts expect Radiopharm Theranostics Ltd to report earnings per share of -2.76 for 2027, against a range of -2.90 to -2.62. The most recent reported year, 2026, came in at -3.86, a 62.2% miss against the -2.38 consensus.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -31.54 | -20.79 | -25.29 | -3.46 | -3.86 | - | - | ||
| High Estimate | -20.60 | -15.49 | -18.42 | -4.49 | -2.25 | -2.62 | -3.50 | ||
| Low Estimate | -23.90 | -18.27 | -22.40 | -5.19 | -2.51 | -2.90 | -4.14 | ||
| Consensus Estimate | -22.25 | -16.88 | -20.41 | -4.84 | -2.38 | -2.76 | -3.82 |